about
Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclaseEffects of inhaled nitric oxide on regional blood flow are consistent with intravascular nitric oxide deliveryPlatelet inhibition by nitrite is dependent on erythrocytes and deoxygenationEnzymatic function of hemoglobin as a nitrite reductase that produces NO under allosteric control.The role of nitrite in neurovascular coupling.Inhibitory effect of nitrite on coagulation processes demonstrated by thrombelastography.Genetic diseases of hemoglobin: diagnostic methods for elucidating beta-thalassemia mutations.Identification and characterization of mechanistically distinct inducers of gamma-globin transcriptionEffect of blood nitrite and nitrate levels on murine platelet function.The reaction of cell-free oxyhemoglobin with nitrite under physiologically relevant conditions: Implications for nitrite-based therapies.Increased reticulocytosis during infancy is associated with increased hospitalizations in sickle cell anemia patients during the first three years of life.A flow cytometric analysis of the inhibition of platelet reactivity due to nitrite reduction by deoxygenated erythrocytes.Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailabilityErythrocytes are the major intravascular storage sites of nitrite in human blood.Hypoxia, red blood cells, and nitrite regulate NO-dependent hypoxic vasodilationJAK-STAT and AKT pathway-coupled genes in erythroid progenitor cells through ontogenyDietary nitrite and nitrate: a review of potential mechanisms of cardiovascular benefits.Effect of storage on levels of nitric oxide metabolites in platelet preparationsThe measurement of blood and plasma nitrite by chemiluminescence: pitfalls and solutions.Acute erythropoietin cardioprotection is mediated by endothelial response.The reaction between nitrite and oxyhemoglobin: a mechanistic studyIn vivo reduction of cell-free methemoglobin to oxyhemoglobin results in vasoconstriction in canines.Hemoglobin research and the origins of molecular medicine.Effects of nitric oxide on red blood cell development and phenotype.Effect of storage levels of nitric oxide derivatives in blood components.Stimulated stromal cells induce gamma-globin gene expression in erythroid cells via nitric oxide production.Nitric oxide from nitrite reduction by hemoglobin in the plasma and erythrocytes.The active site of staphylococcal nuclease: paramagnetic relaxation of bound nucleotide inhibitor nuclei by lanthanide ionsModifications of RNA processing modulate the expression of hemoglobin genesHydroxyurea increases eNOS protein levels through inhibition of proteasome activity.Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells.Preparation and properties of nickel hemoglobin.S-Nitrosohemoglobin is unstable in the reductive erythrocyte environment and lacks O2/NO-linked allosteric function.Oxidation of iron-nitrosyl-hemoglobin by dehydroascorbic acid releases nitric oxide to form nitrite in human erythrocytes.Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells.Increasing hemoglobin oxygen saturation levels in sickle trait donor whole blood prevents hemoglobin S polymerization and allows effective white blood cell reduction by filtration.Overexpression of GATA-2 inhibits erythroid and promotes megakaryocyte differentiation.Randomization in clinical trials of titrated therapies: unintended consequences of using fixed treatment protocols.To publish or not to publish?The solubility of hemoglobins A and S reconstituted with various metalloporphyrins.
P50
Q24554376-E035963E-26F8-4BAB-83DE-670A0BB53AFFQ28344146-4B4AEAA7-F30C-4020-A90B-4D7C34153856Q28732676-7A881122-8CE0-48B8-99C0-BEADC84422AEQ33901706-8D5296B2-BF20-4956-80E9-98358AFA7B15Q33963129-271589B0-D5E4-4410-8754-0DB87DD8D17DQ34047105-4711FBE4-8F6D-4DA2-B848-715EFD7107BAQ34238934-C39D88E6-2E23-410A-87CE-F9C60B5B4541Q34313801-FFE44130-36FB-45DE-BAAD-1A876137AB1AQ34577209-9E830AF4-FF7D-4DC9-8CF8-91287DB0E57EQ34880703-F99C7205-9039-4C2A-AC13-0CCB78459654Q34947693-78346542-FFA2-4C0D-A729-0F638042F717Q35124111-69CDC9EB-EE5D-4D36-ABA5-B1A68FD14FCBQ35750972-426EFC57-1748-4308-81E8-14FDF96E8E42Q35847971-2F645865-07F8-4913-B5B3-AB32B0E80488Q35849284-F55C0998-30DD-4CCC-A9A2-7F29C067EBACQ36143389-C6711935-62C3-4FA3-9B46-FEDB564CAF57Q36372712-1474FB4E-86C7-425F-9F76-B25587DB8685Q36542439-D354D75F-2F12-41CE-A0BF-14AD8E8865C7Q36545307-18FF826C-73CF-4D71-91E0-28EB308EF3E8Q36694644-E4F155BC-40FE-4E4C-9648-33C2ADE1A059Q36741493-205617DD-C525-417A-BD29-66C5CDB47D66Q36941158-044B1653-56DF-4868-8358-CE1C179A4AC5Q36969792-2E60EA4A-8123-43BD-987A-33C9DBEEBC04Q37087640-2E5E96AB-8DE3-42B6-A6B7-7BB623599BCEQ37272562-23A20249-4F5F-4E4F-BAB4-27A0F294A709Q37356342-61AEFD20-8704-478D-B1F4-30B014270C0BQ37399243-99F1E4D8-8D10-4225-A613-0AD6EBD30FB6Q37453034-5B841588-50E8-4557-AC0A-020E3000584FQ37549347-CFC93ED6-525E-48B1-A75E-7471BA49A714Q40169990-A775D9BE-A721-447A-A7BF-24EDE28D9E6EQ40306750-506F1C6F-0342-4356-9997-304402674067Q41435755-302D8FA5-87F1-4EA2-91D8-D7E0C5F974D6Q42521618-4BB1D1D2-A8F2-4005-8F00-1026ABA2B99CQ42524090-DA05D431-7AA2-45E3-A495-2E5840CB0A93Q44942679-45BD9B04-1EC6-4537-871E-DE82C20E5FE5Q45023236-B0BEA74F-02E5-49A3-A9DE-43DFCCDB218CQ52541952-42D46473-C26F-4E79-9EA7-7DE8A22D888CQ52578532-E05D49F4-4FEE-4BC7-B75A-19955F8B098BQ53311248-3E00402A-B73F-4437-A5B4-965EC1C2806CQ53730330-08ED0F78-ECD8-46B9-A4B4-93EB90F4C0B3
P50
description
American medical researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alan Neil Schechter
@en
Schechter AN
@ast
Schechter AN
@es
Schechter AN
@nl
Schechter AN
@sl
type
label
Alan Neil Schechter
@en
Schechter AN
@ast
Schechter AN
@es
Schechter AN
@nl
Schechter AN
@sl
altLabel
Schechter AN
@en
prefLabel
Alan Neil Schechter
@en
Schechter AN
@ast
Schechter AN
@es
Schechter AN
@nl
Schechter AN
@sl
P106
P1153
7101856759
P31
P496
0000-0002-5235-9408